Introduction {#sec1-0969141317692611}
============

Newborn screening (NBS) offers the opportunity for early diagnosis and improved outcome in patients with cystic fibrosis (CF).^[@bibr1-0969141317692611][@bibr2-0969141317692611]--[@bibr3-0969141317692611]^ It is performed worldwide but with considerable variability in strategies.^[@bibr4-0969141317692611],[@bibr5-0969141317692611]^ Important drawbacks include false-positive test results, detection of carriers, infants who screen positive but with inconclusive diagnosis (CFSPID), and missed CF cases. In the French newborn CF screening programme, a centralized monitoring process was implemented by the Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant (AFDPHE) to collect data from screening laboratory centres (22 laboratories for immunoreactive trypsinogen (IRT) measurements, 9 for mutational analysis, 22 regional NBS centres, and 37 CF centres) and to optimize screening strategies with adjustments to biological cut-off levels, mutation panels, or changes in the algorithm. The objective was to attain European Cystic Fibrosis Society best practice standards of care^[@bibr6-0969141317692611]^ in terms of positive predictive value (PPV), sensitivity, ratio of patients diagnosed CF:CFSPID, and time to diagnosis. We analysed and summarized a retrospective evaluation of the national programme since 2002.

Methods {#sec2-0969141317692611}
=======

Screening algorithm {#sec3-0969141317692611}
-------------------

The CF-NBS programme employed a three-tiered algorithm with an initial IRT-1 assay (Delfia Neonatal IRT kit -- Perkin Elmer) at day 3, followed by a *CFTR* panel mutation testing (CF20 Elucigene® kit then CF30 from 2004) when the IRT result was above the cut-off and if written informed consent was obtained on the back of the Guthrie card. (Note: CF30 Elucigene® kit (legacy mutation nomenclature): F508del; I 507del; 1078delT; 1717-1 G \> A; 2183AA \> G; 3659delC; 3849 + 10kbC \> T; 621 + 1G \> T; A455E; E60X; G542X; G551D; N1303K; R1162X; R117H; R334W; R347P; R553X; S1251N; W1282X; 1811 + 1,6kbA \> G; 2789 + 5G \> A; 3120 + 1G \> A; 3272-26A \> G; 394 delTT; 711 + 1G \> T; G85E; Y1092X; Y122X; W846X.) A second IRT was performed at day 21 (IRT-2), if there was no parental written consent or no identified mutation. In 2003 and 2004, analysis of data by the technical committee of the AFDPHE led to changes in screening strategy to optimize the programme (as previously published^[@bibr7-0969141317692611]^) by simultaneously increasing the IRT-1 cut-off (from 60 to 65 µg/L) to maintain the target of the 0.5% positive test, and the IRT-2 cut-off (from 30 to 40 µg/L) because of the very low rate of diagnosed CF in the absence of detected mutations. The IRT-2 sample was maintained in cases with no written consent for mutational analysis, but was restricted to newborns with no identified mutation and a very high IRT-1 (≥100 µg/L).

Definitions and terminology {#sec4-0969141317692611}
---------------------------

### Diagnosis {#sec5-0969141317692611}

Diagnosis in newborns screen positive for CF was confirmed by a sweat chloride concentration of ≥60 mmol/L (some centres used conductivity, with cut-off values published by Nguyen et al.^[@bibr8-0969141317692611]^), or two CF causing *CFTR* mutations *in trans*,^[@bibr9-0969141317692611]^ with the exception of those carrying a c.3718-2477 C \> T (3849 + 10kbC \> T) mutation known to be associated with sweat test values below the cut-off.

### CFSPID {#sec6-0969141317692611}

This is a descriptive rather than a diagnostic label, as these infants do not have disease, but have a number of risk factors for developing CF-related conditions in the future. It is applied to those who screened positive with either a normal sweat chloride result and two *CFTR* gene mutations, at least one of which had unknown phenotypic consequence, or an intermediate sweat chloride result and one or no mutations.^[@bibr10-0969141317692611]^

### Carriers {#sec7-0969141317692611}

Newborns screened positive were labelled as carriers based on identification of one mutation in the CF30 kit and a normal sweat chloride concentration \<30 mmol/L.

### Pending status {#sec8-0969141317692611}

This refers to screen positive infants referred at a CF centre where the CF physician cannot provide a definite conclusion, either because the sweat test or the allele mutational analysis is still ongoing.

### PPV {#sec9-0969141317692611}

This is the number of infants with a true positive NBS test divided by the total number of positive tests.

### Sensitivity {#sec10-0969141317692611}

This is the number of true positive NBS results as a percentage of the total CF population (true positive and false-negative); for the calculation we included in the analysis cases missed by NBS that resulted in delayed diagnosis (excluding meconium ileus (MI) or prenatal diagnosis (PND)).

Programme surveillance {#sec11-0969141317692611}
----------------------

For each screen positive infant requiring referral for sweat testing, a pre-filled document (including IRT results, molecular genetics, term pregnancy, birth weight and length) was faxed by the regional NBS centre to the nearest CF centre to the home address; receipt was confirmed by telephone. The CF physician called the family to arrange an appointment for a sweat test on the same or the following day, and then completed the form, noting date of initial visit, symptoms, sweat test results and outcome, and with a conclusion code corresponding to: CF (CF or CFSPID and including MI, PND, and familial history of CF); non-CF; pending status; death; or lost to follow-up). The form was returned to the regional NBS centre and forwarded quarterly, after partial de-identification, to the centralized NBS structure (AFDPHE), where a referent CF physician and national data manager were in charge of monitoring. CFSPID was identified centrally, case by case, based on *CFTR* mutations^[@bibr9-0969141317692611]^ and sweat test results. A board of physicians, a midwife, an ethicist, and biologists met monthly to discuss all NBS programmes, and every three months the technical committee reviewed monthly distribution of IRT results and molecular genetics, refining practical aspects of the CF NBS programme. Compliance with the algorithm, time to initial visit to the CF centre, sweat test results, and complete genotype in those diagnosed with CF or identified as CFSPID were tracked. Regular queries and updates of initial missing information were part of monitoring. In addition, an annual questionnaire was sent both to CF and regional NBS centres, to collect cases missed by NBS but diagnosed based on symptoms. Combined analysis of laboratory and clinical outcome data, so as not to increase the rate of missed cases, led to changes in IRT cut-off levels and screening strategies for limiting the number of false-positive cases and detecting infants identified as CFSPID. The AFDPHE national database was recently linked to the French CF patient registry database^[@bibr11-0969141317692611]^ to provide the most comprehensive data.

Statistical analysis {#sec12-0969141317692611}
--------------------

We evaluated the characteristics of the screening protocol, mainly PPV, sensitivity, and incidence. Qualitative variables are described as numbers and percentages, and quantitative variables as medians \[Q1--Q3\]. Incidence rates are given with their 95% confidence interval (CI). For comparing groups, chi-square test was used for comparing medians, and the student *t*-test for percentages and other quantitative variables. Level of significance (p-value) was set at 5%. Statistical analyses were performed using SPSS Statistics v19.0 software.

Results {#sec13-0969141317692611}
=======

Study population {#sec14-0969141317692611}
----------------

Of 10,046,581 babies screened from 2002 to December 2014 ([Table 1](#table1-0969141317692611){ref-type="table"}), 53,848 (0.54%) screened IRT-positive at day 3. For 1135 of these infants (2.1%), parental informed consent for DNA analysis was missing, and IRT-2 sampling was undertaken. The rate of loss to follow-up, including death, was 3.3%. At the end of screening, 2045 infants either met diagnostic criteria for CF (n = 1765) or were identified as CFSPID (n = 280). Only 39 cases out of 7872 infants referred to a CF centre had pending status. [Table 1](#table1-0969141317692611){ref-type="table"} summarizes data from the two periods (2002--2004 and 2005--2014) defined by flow chart changes described above (see Methods). These modifications significantly reduced the number of positive screening tests in agreement with the predefined target of 0.50%, the number of positive screens for an IRT-2 and, importantly, the rate of infants referred for sweat testing. Programme PPV improved from 0.16 to 0.31 (p \< 0.0001). The ratio CF:CFSPID (6.3:1) remained similar over time. The disease incidence remained stable over time. Programme sensitivity was stable at 0.95; this was evaluated over a shorter period (2002--2013), to allow a sufficient follow-up period for identifying symptomatic missed cases. Table 1.Data on the newborn CF screening population during 2002--2014 in accordance with changes in the algorithm and data on the false negative cases during 2002--2013.Study period2002--20142002--20042005--2014p-valueNewborns screened for CF, N  Screened positive IRT day 3, N (% of screened population) --Absence of WIC, N (%) --Lost to follow-up or death, N (%)10,046,581 53,848 (0.54) 1131 (2.1) 1803 (3.3)1,928,969 13,808 (0.72) 323 (2.3) 839 (6.1)8,117,612 40,040 (0.49) 808 (2.0) 964 (2.4)\<0.0001^c^ \<0.05^c^ \<0.0001^c^Kit CF30 Elucigene® CFTR analysis N (% of screened population) Two mutations, N (%) 1 mutation, N (%) 0 Mutation, N (%)52,717 (0.52) 1490 (2.8) 4417 (8.4) 46,810 (88.8)13,485 (0.70) 309 (2.3) 1147 (8.5) 12,029 (89.2)39,232 (0.48) 1181 (3.0) 3270 (8.3) 34,781 (88.7)\<0.0001^c^ \<0.0001^c,d^ NS^c^ NS^c^Positive IRT day 21 N (% of screened population)1968 (0.019)1223 (0.063)745 (0.009)\<0.001^c^Infants referred to a CF centre N (% of screened positive)7872 (14.6)2676 (19.3)5196 (12.9)\<0.0001^c^Diagnosis concluded, N --CF, N (% of concluded diagnosis) *Detected with MI or PND*, *N* (%) -- CFSPID, N (% of concluded diagnosis) -- Ratio CF/CFSPID2045 1765 (86.3) 291 (16.5) 280 (14.2) 6.3/1441 379 (85.9) 64 (16.9) 62 (14.1) 6.1/11604 1386 (86.4) 227 (16.4) 218 (13.6) 6.3/1NS^c^ NS^c^ NS^c^ NS^c^Pending infant status N (% of referrals to a CF centre)39 (0.5)039 (0.75)\<0.0001^c^Positive predictive value (95% CI)0.26 \[0.25; 0.27\]0.16\[0.15; 0.18\]0.31\[0.30; 0.32\]\<0.0001^c^Incidence \[95% CI\]^a^1/4913 \[1/5135; 1/4709\]1/4374 \[1/4824;1/4001\]1/5061 \[1/5321;1/4825\]NS^b^Number of newborn screened up to 2013 Diagnosis confirmed, N (CF or CFSPID) False negative w/o MI, PND, N (*CF or CFSPID*) Sensitivity overall (95% CI) Sensitivity for CF (95% CI) Sensitivity for CFSPID (95% CI)9,233,593 1883 (1621 or 262) 108 (86 or 22) 0.946 \[0.936; 0.956\] 0.950 \[0.939; 0.960\] 0.923 (0.892; 0.954)1,928,969 441 (379 or 62) 25 (19 or 6) 0.946 \[0.926; 0.967\] 0.952 \[0.931; 0.973\] 0.912 \[0.844; 0.979\]7,304,624 1442 (1242 or 200) 83 (67 or 16) 0.946 (0.934; 0.957) 0.949 \[0.937; 0.961\] 0.926 (0.891; 0.961)NS^b^ NS^b^ NS^b^[^1]

Reported sweat testing results and molecular genetics {#sec15-0969141317692611}
-----------------------------------------------------

The rate of reporting of sweat test results in infants diagnosed with CF or identified as CFPSID carrying two CF30 mutations, excluding MI or PND, was 1226/1284 (95.5%). In the cohort with MI or PND (228/291), it dropped to 78.3%. For infants carrying one mutation or with no mutations, and excluding cases of MI and PND, CF centres did not provide sweat test results despite reminders, for two out of 470 infants. Nevertheless, infant status was determined based on familial CF history and positive mutational analysis. The CF30 kit identified 87.7% of CF alleles, with a detection rate of ≥80% for all 22 French regions. Mutational analysis in the 2045 infants with CF or identified as CFSPID was 4073/4090 (99.6%), as only 17 alleles were unidentified after *CFTR* next generation sequencing methods, including the search for large rearrangements.

CFSPID and the p.Arg117His mutation {#sec16-0969141317692611}
-----------------------------------

From 2002 to December 2012, 246 CFSPID cases were identified, 133 (54%) of which carried p.Arg117His ([Table 2](#table2-0969141317692611){ref-type="table"}). Infants with p.Arg117His alone and a negative sweat test result were labelled as carriers. Infants carrying two p.Arg117His (n = 12) with a negative sweat test result, compound heterozygous with one p.Arg117His and a sweat test result in the negative or intermediate range (n = 121), were identified as CFSPID. Complementary exploration of the polypirimidine variant in intron 8 *in cis* was exclusively poly T7. A decision-making process for excluding this mutation from the CF30 Elucigene® kit began in 2013. In [Table 2](#table2-0969141317692611){ref-type="table"}, we show that removal of p.Arg117His would ignore 365 carriers and 12 homozygotes. Among the 130 compound heterozygotes, 62 (48%) with a normal sweat test result would be labelled as carriers, and only those with an intermediate/positive sweat test result would be further investigated by *CFTR* sequencing and next generation sequencing, thus identifying p.Arg117His. There were six cases missed by NBS and carrying a p.Arg117His; four were older siblings of positive screened infants, one was a PND, and one was diagnosed based on mild respiratory symptoms at 18 months, with a sweat chloride of 45 mmol/L and a p.Arg117His; T5. Table 2.Characteristics of CF-screened positive cohort carrying at least one p.Arg117His (period 2002--2012, number of newborns screened: 8,420,082).Mutation kit CF30p.Arg117His alonep.Arg117His homozygousp.Arg117His/otherNumber365^[a](#table-fn2-0969141317692611){ref-type="table-fn"}^12^a^130Sweat test Negative, N (%) Intermediate, N (%) Positive, N (%)365 (100) 0 012 (100) 0 062 (47.7) 59 (45.4) 9^[b](#table-fn3-0969141317692611){ref-type="table-fn"}^ (6.9)Symptoms0012Intron 8 polyT7, N (%)--12 (100)130 (100)LabellingCarrierCFSPID^[](#table-fn4-0969141317692611){ref-type="table-fn"}^CFSPID^[](#table-fn4-0969141317692611){ref-type="table-fn"}^/CF[^2][^3][^4]

Time to initial visit at the CF centre and symptoms {#sec17-0969141317692611}
---------------------------------------------------

[Table 3](#table3-0969141317692611){ref-type="table"} shows age at initial sweat test for infants diagnosed with CF, excluding those identified at birth with MI or PND; missing data concerned 7.5%. Infants with CF were seen at a significantly younger age than those identified as CFSPID; however, 12% of the CF cohort was seen after 56 days. At initial visit, infants with CF were more often symptomatic than those identified as CFSPID (p = 0.0001). Rate of respiratory symptoms in the CF cohort increased in those seen beyond 35 days (106/643, 16.5%) compared with those seen earlier (80/735, 10.9%, p \< 0.01). Surprisingly, in 2013, time to initial visit increased to 42 (32--49) days, with a higher rate (38/71, 53.5%) of CF cases seen after 35 days. Table 3.Age and symptoms at initial visit to a CF centre of infants diagnosed with CF and identified CFSPID^a^ (period 2002--2014, number of newborn screened: 10,046,581).CFCFSPIDp-valueNumber of cases with age reported, (%) Age at initial visit, d^a^ Seen at ≤ 35 days, N (%) Seen at ≤ 56 days, N (%)1378^b^/1474^c^ (93.5) 35 \[28; 45\] 735/1378^b^ (53.3) 1211/1378^b^ (87.9)245^b^/280^c^ (87.5) 46 \[35; 60\] 63/245^b^ (25.7) 172/245^b^ (70.2)\<0.001^f^ \<0.0001^e^ \<0.0001^f^ \<0.0001^f^Symptoms at initial visit, N (%)1106/1765^d^ (62.6)25/280^d^ (8.9)\<0.0001^f^[^5]

Discussion {#sec18-0969141317692611}
==========

This study demonstrates that a rigorous surveillance tracking process can evaluate the performances of a national programme. Missing parental informed consent for DNA analysis was mainly related to newborn hospitalization rather than parental refusal, and all such infants followed the algorithm with IRT-2 sampling. Adjustments in the protocol achieved a PPV of 0.31 while maintaining 95% sensitivity, in agreement with the European Cystic Fibrosis Society Standards of Care.^[@bibr6-0969141317692611]^ Infants carrying one mutation in the CF30 panel were referred for a sweat test, with a diagnosis of CF or labelled CFSPID in 11% ([Table 1](#table1-0969141317692611){ref-type="table"}), while the remaining infants were carriers. We had a very low rate of pending status; 54% were born in 2013--2014, and information on sweat testing and mutations is expected shortly.

We maintained the IRT-2 sampling for sensitivity purposes, because we identified 42 infants with CF (1/18) among the 745 with positive IRT-2, related to screened population diversity and limited *CFTR* panel mutations. In the literature, fail-safe protocols vary from a second IRT sampling to immediate sweat testing in cases of very high initial IRT or expanded mutation panels, such as in Massachusetts; however, low PPV at 0.09^[@bibr12-0969141317692611]^ is considered unacceptable. The UK programme is remarkable for its excellent PPV of 0.75^[@bibr13-0969141317692611]^; it combines a limited panel of four CFTR mutations, followed by a second step panel mutation (29/31 mutations) if only one mutation is detected; this avoids the need for sweat testing in cases with only one mutation after the second-step mutation panel with low IRT-2.

We found strong adherence to sweat testing (95.4%) in those carrying two CF-causing mutations. NBS is not a diagnostic test, and whether or not the infant has CF relies on demonstrating CFTR dysfunction; furthermore, sweat testing is a safeguard against mislabelling newborns, laboratory errors, or mutations carried *in cis*.^[@bibr14-0969141317692611]^ Improving adherence to sweat testing remains challenging in many European countries^[@bibr15-0969141317692611]^ and in the US, with nearly 24% of cases without sweat test results.^[@bibr16-0969141317692611]^

We report comprehensive identification of both alleles after complete *CFTR* analysis,^[@bibr17-0969141317692611]^ when applicable. This is in agreement with diagnostic criteria for CF^[@bibr6-0969141317692611]^ defined by sweat chloride above 59 mmol/L and/or two CF-causing *CFTR* mutations *in trans.* Mutation panel sizes vary from a few mutations to a comprehensive panel, as in California^[@bibr18-0969141317692611]^ or Poland,^[@bibr19-0969141317692611]^ thus identifying many more carriers and CFSPID; this is in disagreement with the European Cystic Fibrosis Society Standards of Care.^[@bibr6-0969141317692611]^

One of the most controversial negative impacts of genetic analysis in NBS algorithms is detection of babies carrying at least one non CF-causing mutation, as most of these infants will remain asymptomatic. The p.Arg117His mutation was overrepresented^[@bibr17-0969141317692611]^ consistently on a T7 background, considered neutral in light of the statement that p.Arg117His T7 should no longer be considered a CF-causing mutation in asymptomatic newborn infants.^[@bibr20-0969141317692611]^ The technical committee of the AFDPHE validated the consequences of p.Arg117His removal (see [Table 2](#table2-0969141317692611){ref-type="table"}); CF centres then agreed to remove this mutation (61%) and Elucigene® confirmed the feasibility of CE-IVD certification. The new kit excluding p.Arg117His was introduced in 2015. Analysis of data collected in 2015 showed dramatic improvement in the ratio CF/CFSPID (9:1), a decrease in carriers, and increased PPV (0.34). Thus, in neonates who screened positive with one or no CFTR mutation and a sweat test ≥30 mmol/L, a search for other mutations was required, and p.Arg117His was included in this second-line panel. In the literature, very few case reports carrying a severe mutation and p.Arg117His T7 had early pulmonary manifestations.^[@bibr21-0969141317692611],[@bibr22-0969141317692611]^ Removal of p.Arg117His cannot be extrapolated to countries in which the polypirimidine variant in intron 8 *in cis* is on a T5 background, due to its associated pathogenicity. Recently, Norway^[@bibr23-0969141317692611]^ introduced NBS for CF with a mutation panel immediately excluding p.Arg117His T7, and The Netherlands removed it in July 2016.

Median time to initial CF centre visit in those diagnosed with CF (excluding MI and AND) was 35 days,^[@bibr24-0969141317692611]^ except for 2013. These cases were individually analysed at each of the four main steps of the screening protocol: delay from IRT sampling to results (\>10 days: n = 4), mailing of Guthrie cards to the genetic laboratory (\>10 days: n = 3), mutational analysis (\>15 days: n = 15), and initial visit to the CF centre (\>15 days: n = 32). The AFDPHE board and the technical committee sent letters to all partners providing suggestions for improvement, such as sending Guthrie cards to genetic laboratories daily rather than weekly, immediate secure faxing of positive results of mutational analysis to the regional NBS centre, greater vigilance during holidays when laboratories and CF centres are understaffed, and request for an explanation if referral (defined as the date on which the infant was first seen, rather than the date of successful sweat testing) to a CF centre was delayed. In the following year, 2014, median delay to initial visit returned to a baseline of 35 (28; 41) days. However, 12% of infants with CF were seen beyond 56 days, and this remains a crucial point requiring improvement, as the rate of respiratory symptoms was higher in those seen after 35 days. The European Cystic Fibrosis Society Standards of Care^[@bibr6-0969141317692611]^ statement specifies that "the majority of infants with a confirmed diagnosis after NBS should be seen by the CF specialist team by 35 days and no later than 58 days after birth."

Our study has some limitations. First, we could not provide a case-by-case explanation for non-written informed consent for DNA analysis, as this is not requested on the Guthrie card. In addition, the rate of initial sweat testing failure was not evaluated, and the results reported in the document might relate to older infants.

Our strategy was considered unethical by the National Ethical Committee (No. 57 01/2007), because detection of carriers via *CFTR* analysis was limited to families with an infant having high IRT-1 (1/2000 instead of 1/33 in the general population), but was considered beneficial by many parents in terms of reproductive planning.^[@bibr25-0969141317692611]^ Later, the Ministry of Health (HAS, 2009) concluded that the programme gave satisfactory performance, but confirmed that healthy carrier detection and CFSPID identification were beyond the goals of NBS and should be avoided by alternative strategies. It considered the panel of mutations based on frequencies in the general population to be unfair to ethnic minorities, and requested removal of DNA analysis. Thus, a study comparing the current strategy with IRT/pancreatitis-associated protein (PAP) protocol was conducted on 500,000 newborns in 2010. Data demonstrated non-inferiority in terms of sensitivity, no carrier detection, and a decreased rate of CFSPID identification, but a dramatic decrease in PPV (0.09),^[@bibr26-0969141317692611]^ that represented a major barrier to implementing this strategy. Recently, European experiments combining IRT/PAP/DNA^[@bibr27-0969141317692611][@bibr28-0969141317692611]--[@bibr29-0969141317692611]^ showed similar sensitivities and much better PPV than IRT/PAP, but a residual number of detected carriers and CFSPID. Cost of IRT/PAP/DNA and IRT/DNA strategies was similar. Based on these data, an IRT/PAP/DNA strategy with a similar financial envelope to the current IRT/DNA was submitted to French authorities and to Health Insurance for agreement. Currently, the technical committee of AFDPHE is working on IRT and PAP cut-offs values, and on the usefulness of a safety net for evaluating the feasibility and financial cost.

In summary, despite its worldwide use for many years, NBS for CF presents a number of challenges, including finding a satisfactory balance between positive predictive value, sensitivity, and clinical utility.^[@bibr30-0969141317692611],[@bibr31-0969141317692611]^ Evaluation of the performance of ongoing algorithms must rely on rigorous centralized tracking, aimed at monitoring outcome data. The newborn screening process begins at the maternity ward, but ends at the CF centre, with a definitive conclusion, enabling those diagnosed with CF or identified as CFSPID to rapidly benefit from adequate care management and follow-up. Our data complement an accumulating body of evidence demonstrating that attention must be paid to such ethical considerations as limiting carrier detection and inconclusive diagnosis.
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[^1]: ^a^CF and CFSPID. ^b^Chi square test. ^c^Student\'s *t*-test. ^d^Kit CF20 moved to CF 30. WIC: written inform consent; MI: meconium ileus; PND: prenatal diagnosis; CFSPID: CF Screen Positive, Inconclusive Diagnosis.

[^2]: Exclusion of p.Arg117His would ignore them.

[^3]: All these cases were symptomatic.

[^4]: CFSPID: CF Screen Positive, Inconclusive Diagnosis.

[^5]: ^a^Median \[Q1--Q3\]. ^b^Available data. ^c^Excluding meconium ileus and prenatal diagnosis. ^d^Including meconium ileus and prenatal diagnosis. ^e^Chi square test. ^f^Student\'s *t*-test. CF: cystic fibrosis; CFSPID: CF Screen Positive, Inconclusive Diagnosis.
